GlycoEra AG specializes in the development of innovative glycoengineering technologies aimed at enhancing the therapeutic potential of glycoproteins. Their proprietary platform focuses on the precise modification of glycan structures, which are crucial for the efficacy and safety of biopharmaceuticals. By leveraging advanced glycosylation techniques, GlycoEra aims to optimize the pharmacokinetics and immunogenicity of therapeutic proteins, thereby improving patient outcomes and expanding the applicability of existing drugs.

The company’s pipeline includes a range of products that utilize these glycoengineering technologies to create next-generation biotherapeutics. GlycoEra's approach not only enhances the performance of existing biologics but also facilitates the development of novel therapies that can address unmet medical needs. Their commitment to advancing glycoengineering positions them at the forefront of biopharmaceutical innovation, with the potential to significantly impact the treatment landscape for various diseases.

Switzerland

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

GlycoEra AG

Company Details